A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by activating the mother’s body’s defences to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent coverage when vaccinated 4 weeks before birth
- Antibodies from the mother passed through the placenta protect newborns from day one
- Coverage possible with 2-week gap before early delivery
- Vaccination in third trimester still provides meaningful infant protection
Compelling evidence from the latest research
The performance of the pregnancy RSV vaccine has been established through a extensive research programme carried out throughout England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that half-year window, providing robust and representative data of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation provides healthcare professionals and prospective parents with assurance in the vaccine’s established performance across diverse populations and circumstances.
The results present a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference highlights the vaccine’s critical role in reducing the risk of serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Methodology and scope of study
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection rates and hospital admissions. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology captured actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine works when administered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its threats
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection causes inflammation deep within the lungs and airways, making it extremely challenging for infected babies to breathe and feed adequately. Parents frequently observe their babies visibly struggling, their chests rising whilst they try to pull adequate oxygen into their compromised lungs. Whilst the majority of babies improve through supportive care, a small but significant number die from respiratory syncytial virus complications each year, making immunisation programmes a essential public health priority for protecting the most vulnerable and youngest people in our communities.
- RSV triggers lung inflammation, leading to serious respiratory problems in babies
- Half of all infants contract the virus during their first few months alive
- Symptoms range from mild colds to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV annually
- Small numbers of infants die from RSV complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have highlighted the significance of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies through the placenta.
The guidance from health authorities remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst ensuring strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data shows consistently strong protection irrespective of geographical location.
- NHS trusts deploying multiple messaging strategies to engage with pregnant women
- Inconsistencies across regions in immunisation take-up across England necessitate strategic intervention
- Regional health providers tailoring initiatives to align with community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness delivers real advantages for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the launch of this safeguarding intervention, the 80% decrease in admissions represents thousands of infants protected against severe infection. Parents no more face the upsetting situation of seeing their babies struggle for breath or struggle to eat, symptoms that define severe RSV infections. The vaccine has markedly changed the terrain of neonatal breathing health, offering expectant mothers a active means to safeguard their most vulnerable children during those critical early months.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s promotion of the jab emphasises the transformative consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to expectant mothers during their third trimester, transforming what was once an unavoidable seasonal threat into a manageable health risk.